Zhanar Toktarova

Dr. Zhanar Toktarova

Department of Internal Medicine, NJSC "Kazakh National Medical University named after. S.D. Asfendiyarov",, Almaty, Kazakhstan
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Closed access
DADana Akhmentayeva
Dana Akhmentayeva
Zhanar ToktarovaZhanar Toktarova
Zhanar Toktarova
Aigyul IzhanovaAigyul Izhanova
Aigyul Izhanova
Meiramgul TokbulatovaMeiramgul Tokbulatova
Meiramgul Tokbulatova
AIAssel Issabekova
Assel Issabekova
GZG. Kh. Zhansarina
G. Kh. Zhansarina
Introduction . Hyperglycemia is one of the most common pregnancy complications worldwide. The largest proportion of patients are women with gestational diabetes mellitus, followed by pregnant women with previously diagnosed type 1 and type 2 diabetes. Managing such cases is a complex clinical task requiring close cooperation between specialists in various fields. Aim . To analyze the tactics of managing pregnant women with diabetes mellitus to assess predisposing risk factors. Materials and methods. The analysis of modern data was carried out with an emphasis on the role of diabetes mellitus in developing complications during pregnancy. The databases PubMed, Scopus, Web of Science, and eLibrary were used for the analysis. The search was carried out by keywords: gestational diabetes mellitus, pregnancy complications, metabolic disorders, maternal-fetal outcomes, prevention of diabetes in pregnancy. Results . The level of metabolic control at the stage of pregnancy planning has a significant impact on its course and outcome in women with type 1 and type 2 diabetes mellitus. Pre-pregnancy training and professional support of qualified specialists play a key role, often surpassing мнеthe use of modern technologies such as insulin pumps and continuous glucose monitoring systems. Conclusion . Despite the existing methods of prevention and treatment, there remains a need for further study of individualized approaches to the management of pregnant women with metabolic disorders.

12 November 2026 in Diseases
Verified
Journal Article
Open access
PDF file
Zhanetta MukanovaZhanetta Mukanova
Zhanetta Mukanova
Sholpan Bolatovna ZhangelovaSholpan Bolatovna Zhangelova
Sholpan Bolatovna Zhangelova
Dina Amangeldinovna KapsultanovaDina Amangeldinovna Kapsultanova
Dina Amangeldinovna Kapsultanova
KMKanatbek Mukanov
Kanatbek Mukanov
Zhanar NurbayZhanar Nurbay
Zhanar Nurbay
Nurmukhammad Friba NasrullakyzyNurmukhammad Friba Nasrullakyzy
Nurmukhammad Friba Nasrullakyzy
Background and Objective. Epistaxis is a frequent bleeding manifestation in patients receiving antithrombotic therapy, and its management falls between otolaryngology and cardiology guidance. We aimed to translate the evidence into an operational framework for joint decisions. Methods. PubMed/MEDLINE, Scopus, Embase, and the Cochrane Library were searched (January 2015 through August 2026), current ESC, ACC/AHA, EHRA, AAO-HNS, and SFORL guidance were analyzed, and national clinical protocols of different countries were screened; 67 sources were included. Results. Direct oral anticoagulants were consistently associated with fewer clinically relevant epistaxis events than warfarin, and minor epistaxis led to permanent anticoagulant discontinuation more often than minor bleeding at other sites. No guideline defines epistaxis severity, and guidance diverges on protected dual antiplatelet therapy, bleeding-risk assessment, and the sequence of local hemostasis and drug interruption. We propose a three-tier severity classification (minor, clinically relevant non-major, major) informed by ISTH and BARC definitions, a pragmatic thrombotic risk stratification, and an algorithm with agent-specific decisions. Conclusions. In minor and most clinically relevant non-major episodes, antithrombotic therapy can usually be continued while local hemostasis is achieved; interruption, de-escalation, or reversal should be individualized and reserved for uncontrolled or major bleeding. Effective local hemostasis can help avoid unnecessary interruption of antithrombotic therapy, and otolaryngologists should be part of multidisciplinary teams managing such bleeding.

30 October 2025 in Наука и здравоохранение
Verified
Journal Article
Open access
AZA.S. Zhunuspekova
A.S. Zhunuspekova
MAM.N. Akkaliyev
M.N. Akkaliyev
BAB.A. Ashirov
B.A. Ashirov
JMJamilya Mansurova
Jamilya Mansurova
Meiramgul TokbulatovaMeiramgul Tokbulatova
Meiramgul Tokbulatova
DND.T. Nurgalieva
D.T. Nurgalieva
We describe a case of ST-elevation myocardial infarction in a 74-year-old patient with peripheral artery disease. Despite dual antiplatelet therapy with high-dose clopidogrel, stent thrombosis and recurrent infarction occurred, requiring escalation to ticagrelor. Additionally, a low level of Klotho protein was detected, associated with increased risk of complications. This case highlights the importance of platelet function testing and emerging biomarkers for individualized therapy. Описан случай инфаркта миокарда с подъёмом ST у 74-летнего пациента с поражением периферических артерий. На фоне резистентности к клопидогрелю развился тромбоз стента и повторный инфаркт, что потребовало эскалации терапии до тикагрелора. Дополнительно выявлен низкий уровень белка Klotho, ассоциированный с высоким риском осложнений. Случай подчёркивает значимость тестирования функции тромбоцитов и поиска новых биомаркеров для индивидуализации терапии. 74 жастағы перифериялық артерия ауруы бар науқаста ST сегментінің көтерілуімен миокард инфарктісі жағдайы сипатталған. Жоғары дозадағы клопидогрелмен қос антитромбоцитарлық терапияға қарамастан, стент тромбозы және қайталама инфаркт дамыды, бұл тикагрелорға эскалацияны қажет етті. Сонымен қатар, асқыну қаупінің жоғарылауымен байланысты төмен Klotho ақуызының деңгейі анықталды. Бұл жағдай тромбоциттердің функциясын тестілеудің және жаңа биомаркерлерді қолданудың терапияны жекелендіру үшін маңыздылығын көрсетеді.

Verified
Journal Article
Open access
PDF file
JMJamilya Mansurova
Jamilya Mansurova
AKAnar Kozhabayeva
Anar Kozhabayeva
MKMirgul Kapakova
Mirgul Kapakova
AZAisulu Zhunuspekova
Aisulu Zhunuspekova
AAAinur Abylkhairova
Ainur Abylkhairova
AKAssel Kassymova
Assel Kassymova
Background: Whether plasma α-Klotho carries prognostic value in patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI) is still unclear. Objectives: We set out to examine the links between plasma α-Klotho levels, routine clinical and laboratory findings, the occurrence of acute kidney injury (AKI), and cardiovascular mortality after PCI. Methods: Eighty-six patients with ACS treated by PCI were enrolled in this prospective study. Plasma α-Klotho was measured within 48 h of the procedure. Relationships were assessed by correlation analysis and logistic regression; cardiovascular mortality was tracked for 12 months. Results: Acute kidney injury developed in 30 patients (34.9%), and nine cardiovascular deaths (10.5%) occurred during the year of follow-up. α-Klotho showed positive correlations with platelet count, triglycerides and total protein, and inverse correlations with FIB-4, aspartate aminotransferase, creatinine, GRACE score, contrast volume and international normalized ratio. No significant link was found between α-Klotho and AKI (p = 0.882). Erythrocyte sedimentation rate (OR = 1.090; p < 0.001) and contrast volume (OR = 1.014; p = 0.007) remained independently associated with AKI. In univariable analysis higher α-Klotho levels were linked to lower cardiovascular mortality (OR = 0.648; p = 0.009). Conclusions: Higher plasma α-Klotho concentrations were associated with reduced odds of cardiovascular death in the univariable model. No association with AKI was detected. The mortality results should be regarded as exploratory and do not demonstrate an independent prognostic role.